Electrospun nanocomposite dressing integrating cerium dioxide and collagen accelerates pressure injury healing Authors: Zhikang Mo, Jiani Wu, Huiyu Tan, Caiyan Qian, Yumei Zhong, Lu Zhang, Haibin Chen, Yue Tang Published: 2026 ABSTRACT SummaryPressure injuries (PIs) involve a pathological cycle of oxidative stress, inflammation, and impaired angiogenesis. To address this, we engineered an electrospun nanocomposite dressing—CePC—incorporating cerium dioxide nanoparticles into a polycaprolactone collagen matrix. This dressing could modulate the wound microenvironment. In vitro, it could scavenge reactive oxygen species, protect endothelial cells, enhance vascular endothelial growth factor (VEGF) expression, and reduce pro-inflammatory cytokines. In a murine PI model, the treatment accelerated wound closure, promoted granulation tissue formation and dermal regeneration, and improved functional angiogenesis. Mechanistically, the dressing shifted the macrophage phenotype from a pro-inflammatory to a pro-healing state. These findings demonstrate a strategy that combines nanomaterials and biomaterials to regulate inflammation and vascularization, providing a potential therapeutic approach for PI repair.Subject areas: biotechnology, bioengineering, materials science Introduction Pressure injuries (PIs), also known as pressure ulcers or bedsores, represent a major clinical challenge, particularly in immobilized, elderly, and diabetic patient populations.1 These chronic wounds are characterized by a complex and self-perpetuating pathological microenvironment featuring persistent inflammation, excessive oxidative stress, impaired angiogenesis, and insufficient extracellular matrix remodeling.2,3 This hostile milieu leads to stalled healing, frequent infection, and significant patient morbidity and mortality.4 Among various therapeutic nanomaterials, cerium dioxide nanoparticles (nCeO2) have emerged as a promising candidate for wound healing applications due to their unique redox-active properties.5,6 nCeO2 can mimic key antioxidant enzymes such as superoxide dismutase and catalase, effectively scavenging reactive oxygen species (ROS) that are excessively produced in chronic wounds.7 By alleviating oxidative stress, nCeO2 has been shown to reduce inflammation, protect cells from damage, and indirectly promote pro-healing processes.8,9 However, the clinical translation of free nCeO2 is hampered by challenges related to localized delivery, potential aggregation, and uncontrolled biodistribution.10 To address these limitations, researchers have integrated nCeO2 into various biomaterial carriers. Electrospinning technology has gained widespread attention for fabricating wound dressings, as it can produce nanofibrous membranes that closely mimic the structure of the native extracellular matrix.11 These membranes offer high porosity for gas exchange and exudate management, a tunable degradation profile, and the ability to serve as a reservoir for the sustained release of therapeutic agents.12,13 Several studies have successfully incorporated nanoparticles into electrospun fibers made from synthetic polymers like polycaprolactone (PCL), demonstrating improved antioxidant and antibacterial properties.14 However, many existing composites utilize nanoparticles with less controlled morphologies or larger sizes, which may limit their catalytic efficiency and biocompatibility.15,16 Furthermore, purely synthetic scaffolds often lack the inherent bioactivity needed to optimally guide cellular behavior and tissue regeneration.17,18 To overcome these limitations, we hypothesize that integrating ultra-fine, morphologically defined nCeO2 into a bioactive electrospun composite will yield a synergistic therapeutic effect. In this study, we synthesized square-shaped, ultra-fine nCeO2 (∼5 nm), with a high catalytic surface area, and incorporated them into a PCL-based electrospun membrane. More importantly, we further enhanced the bioactivity by co-electrospinning with type I collagen, a key natural component of the dermal matrix known to promote cell adhesion, proliferation, and differentiation. The resulting PCL-collagen/nCeO2 (CePC) composite membrane is designed to leverage multiple advantages: (1) the potent and sustained ROS-scavenging ability of well-dispersed, ultra-fine nCeO2 to mitigate oxidative stress; (2) the biomimetic nanofibrous structure of the electrospun scaffold for optimal wound coverage and cell infiltration; and (3) the bioactive cues from collagen to actively promote cellular functions and tissue integration. We systematically evaluated the physicochemical properties, biocompatibility, antioxidant capacity, and in vitro pro-angiogenic effects of CePC. Finally, its therapeutic efficacy in modulating inflammation, promoting angiogenesis, and accelerating wound closure was rigorously validated in a clinically relevant murine PI model. This work presents a rational design of a multifunctional nano-biocomposite dressing, with the potential to actively reprogram the chronic wound microenvironment for enhanced healing. Results Design and characterization The successful synthesis and integration of nCeO2 into the electrospun membranes were systematically confirmed through a series of physicochemical characterizations. Initially, the morphology and size distribution of the synthesized nCeO2 were examined. Transmission electron microscopy (TEM) images revealed that the nanoparticles possessed a well-defined square morphology (Figure 1A). High-resolution aberration-corrected TEM (AC-TEM) further confirmed their high crystallinity, displaying clear lattice fringes corresponding to the fluorite structure of CeO2 (Figure 1B). The surface chemical state of nCeO2 was analyzed by X-ray photoelectron spectroscopy (XPS). The XPS spectrum (Figure 1C) confirmed the coexistence of Ce3+ and Ce4+ oxidation states. Dynamic light scattering (DLS) analysis indicated a narrow size distribution, with a hydrodynamic diameter of approximately 4.97 nm, confirming the ultra-fine nature of the synthesized particles (Figure 1D). Characterization of CePC (A and B) Representative TEM image (A) and AC-TEM image of nCeO2 (B). Scale bars: 50 nm (A) and 10 nm (B). (C and D) XPS (C) and DLS (D) profiles of nCeO2. (E) Representative SEM images of PCL, P/C, and CePC. Scale bars: 10 μm. (F–I) Porosity (p = 0.009 for PCL vs. CePC; p = 0.6457 for PC vs. CePC) (F), swelling ratio (p = 0.008 for PCL vs. CePC) (G), tensile stress and elastic modulus (H), and degradation profiles (I) of the different electrospun scaffolds/membranes. Each measurement was conducted in three technical replicates; error bars represent the mean ± SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s HSD post hoc test. ns, not significant; ∗∗, p < 0.01; and ∗∗∗, p < 0.001. Subsequently, the fabricated electrospun membranes were characterized. Scanning electron microscopy (SEM) images demonstrated that all membranes—pure PCL, PCL/nCeO2 (P/C), and CePC—exhibited uniform and randomly oriented fibrous structures with interconnected pores. The average fiber diameter of the CePC membrane was found to be slightly increased compared with that of pure PCL, likely due to the incorporation of collagen and nCeO2. Importantly, the fibrous architecture was well preserved without apparent nanoparticle aggregation, indicating successful and homogeneous dispersion of nCeO2 within the polymer matrices (Figure 1E). The physical and mechanical properties essential for wound dressing applications were quantitatively evaluated. The porosity of the membranes remained high and showed significant differences among the PCL group and CePC group (Figure 1F). The swelling ratio of the CePC membrane was significantly higher than that of pure PCL and P/C (Figure 1G). To further investigate the surface properties underlying this enhanced hydrophilicity, static water contact angles were measured (Figure S1). The CePC membrane exhibited the lowest contact angle (43.7° ± 3.2°), confirming its superior surface wettability compared with PCL (85.6°± 4.3°) and P/C (48.4° ± 3.8°). Mechanical testing revealed that the incorporation of nCeO2 and collagen significantly improved the tensile strength and elastic modulus of the membranes (Figure 1H). The CePC membrane exhibited the highest mechanical robustness. Furthermore, the in vitro degradation profiles were assessed (Figure 1I). While the pure PCL membrane degraded slowly, the degradation rates of the P/C and CePC membranes were found to be significantly accelerated. The in vitro release behavior of nCeO2 from the CePC electrospun membrane was investigated over a 28-day period, using ICP-MS analysis. As shown in Table S2, the release of cerium ions exhibited a biphasic pattern characterized by an initial burst release followed by a sustained and gradual release phase. During the first 24 h (day 1), approximately 18.5% ± 2.1% of the loaded nCeO2 was released. Subsequently, the release rate slowed considerably, with the cumulative release reaching 32.7% ± 3.0% by day 7 and 48.2% ± 4.1% by day 14. From day 14 to day 28, the release profile entered a plateau phase, with the cumulative release increasing modestly to 56.8% ± 4.8% at the end of the study period. Biocompatibility and biosafety The safety profile of the synthesized nCeO2 was first assessed using HaCaT keratinocytes, human umbilical vein endothelial cells (HUVECs), and L929 fibroblasts. The MTT assay (Figure 2A) revealed a significant inhibition of cell proliferation when the nCeO2 concentration was increased from 75 to 100 μg/mL after co-incubation. Corroborating this finding, the CCK-8 assay demonstrated negligible cytotoxicity across the same concentration range following co-incubation with CePC membranes prepared with corresponding nCeO2 concentrations (Figure 2B). Cell viability remained consistently above 95% compared with the control group at concentrations of 75 μg/mL and below. Biocompatibility assessment of CePC (A) Effect of nCeO2 at different concentrations on cell proliferation, determined by the MTT assay. (B) Cytotoxicity of nCeO2 at different concentrations, measured by the CCK-8 assay. HaCaT: 75 μg/mL vs. 100 μg/mL, p < 0.0001; HUVEC: 75 μg/mL vs. 100 μg/mL, p < 0.0001; L929: 75 μg/mL vs. 100 μg/mL, p < 0.0001. (C) H&E staining of vital organs 28 days post-wound application. Scale bars: 200 μm. (D) Hematological analysis at different time points post-wound application. p = 0.7517, day 1 vs. day 3; p = 0.9800, day 3 vs. day 5; p = 0.4864, day 5 vs. day 7. (E) In vitro cytocompatibility assessment. (F) In vivo degradation profiling. n = 3 biologically independent samples; error bars represent the mean ± SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s HSD post hoc test. ns, not significant; ∗∗∗, p < 0.001. To evaluate the in vivo biosafety of the CePC membrane, a comprehensive analysis was conducted in a PI model. Following 28 days of wound application, major vital organs, including the heart, liver, lungs, and kidneys, were harvested for histopathological examination. Hematoxylin and eosin (H&E) staining (Figure 2C) showed well-preserved tissue architecture and clear cellular morphology in all groups, with no evidence of pathological lesions, necrosis, or abnormal inflammatory infiltration. Complementing the histological assessment, a longitudinal hematological analysis was performed. Key blood parameters, including white blood cell (WBC), red blood cell (RBC), and platelet (PLT) counts, were analyzed at multiple time points post-wound treatment and found to remain within normal physiological ranges throughout the study period (Figure 2D). CePC attenuates oxidative stress, suppresses inflammation, and promotes angiogenic potential in HUVECs To investigate the cellular protective mechanisms of the CePC membrane, we evaluated its ability to mitigate oxidative stress and its downstream effects in HUVECs. Using a fluorescent DCFH-DA probe, we first assessed intracellular ROS levels in HUVECs under H2O2-induced oxidative stress. Fluorescence imaging and quantification revealed a dramatic accumulation of ROS in the H2O2-only group (Figures 3A and 3B). Treatment with the CePC membrane extract, however, resulted in a significant attenuation of this fluorescence signal. The pure PCL or P/C film group demonstrated significantly stronger ROS-scavenging capacity than the H2O2 group. CePC promotes cell proliferation by attenuating HUVEC senescence (A and B) ROS detection using a fluorescent probe (A), and the corresponding quantification of fluorescence intensity (B). Scale bars: 200 μm (A). (C) Assessment of cell proliferation in different treatment groups by the MTT assay. (D–F) qPCR analysis of the transcriptional levels of IL-6 (D), IL-1β (E), and the pro-angiogenic growth factor VEGF (F). (G and H) HUVEC angiogenesis assay (G) and tube formation quantification (H). Scale bars: 500 μm (G). For H2O2 vs. H2O2 + CePC, p = 0.0002 (B); p < 0.0001 (D); p < 0.0001 (E); p < 0.0001 (F); and p < 0.0001 (H). Error bars indicate the mean ± standard deviation, n = 3 biologically independent samples. Statistical significance was determined by one-way ANOVA followed by Tukey’s HSD post hoc test. ns, not significant; ∗, p < 0.05; ∗∗, p < 0.01; and ∗∗∗, p < 0.001. The MTT assay was employed to evaluate whether alleviating ROS could restore the cellular metabolic activity. Consistent with the ROS data, while H2O2 exposure severely impaired HUVEC proliferation, the CePC group demonstrated a significant and nearly complete restoration of cell viability (Figure 3C). We next examined the transcriptional response of key inflammatory and angiogenic mediators by using qPCR. H2O2 stimulation significantly upregulated the expression of pro-inflammatory cytokines IL-1β and IL-6 (Figures 3D and 3E). Treatment with CePC membrane extract markedly suppressed the transcription of both cytokines, achieving levels comparable to or even lower than those of the untreated control. In striking contrast, the expression of the pro-angiogenic master regulator—vascular endothelial growth factor (VEGF)—displayed an inverse pattern (Figure 3F). H2O2 stress suppressed VEGF mRNA expression, but this suppression was effectively reversed in the CePC-treated group, where VEGF levels were significantly higher than that in all other treatment groups. The cytoprotective mechanism of CePC was further elucidated through a series of functional and molecular analyses. H2O2 exposure severely impaired HUVEC proliferation, while CePC treatment restored cell viability to near-control levels. This anti-senescence effect was corroborated by reduced ROS levels (Figure 3B), suppression of SASP-related cytokines (Figures 3D and 3E), and activation of the Nrf2/HO-1 antioxidant pathway (Figure S2). As shown in Figure S2, H2O2 alone moderately increased Nrf2 and HO-1 expression, reflecting an endogenous antioxidant response; however, CePC treatment significantly enhanced both proteins under oxidative stress, while P/C or PCL membranes showed no such effect. Consequently, this multifaceted antioxidant and anti-senescence action enabled CePC to directly promote HUVEC tube formation in vitro ((Figures 3G and 3H). In vivo therapeutic efficacy of CePC in promoting vascularized healing of PIs Based on the cytoprotective and pro-angiogenic activities of the CePC membrane observed in vitro, we further evaluated its therapeutic potential in a clinically relevant murine pressure ulcer model (Figure 4A). During pressure ulcer induction, wound progression was macroscopically monitored at 0, 6, 12, 24, and 48 h post-induction. Macroscopic observation over a 14-day healing period revealed a significantly accelerated healing rate in the CePC-treated group (Figure 4B). By day 14, wounds in the CePC group were nearly completely re-epithelialized, in contrast to the larger, partially eschar-covered wounds in the sham, PCL, and P/C groups. In vivo application of CePC promotes vascularized healing of pressure ulcer wounds (A) Schematic of the animal experimental design. (B) Macroscopic appearance of wounds from different groups at indicated time points. (C and D) Representative H&E-stained images of different groups on day 7 (C), and the corresponding wound closure time (D); p < 0.001, H2O2 vs. H2O2 + CePC. Scale bars: 100 μm (C). (E) Dermal thickness of different groups on day 7; p < 0.001, H2O2 vs. H2O2 + CePC. (F) Representative CD31-immunostained images on day 14. Scale bars: 20 μm. (G) Quantitative analysis of vascularized area based on Figure 4D; p < 0.001, H2O2 vs. H2O2 + CePC. (H) Transcriptional level of the pro-angiogenic growth factor VEGF measured by qPCR; p < 0.001, H2O2 vs. H2O2 + CePC. Error bars indicate the mean ± standard deviation; n = 3 biologically independent samples. Statistical significance was determined by one-way ANOVA followed by Tukey’s HSD post hoc test. ns, not significant; ∗, p < 0.05; ∗∗, p < 0.01; and ∗∗∗, p < 0.001. To assess the quality of the regenerated tissue, histological analysis was performed. H&E staining of day 7 wound sections (Figure 4C) demonstrated that CePC-treated wounds exhibited more robust granulation tissue formation, characterized by denser cellular infiltration and more organized extracellular matrix deposition. Measurement of dermal thickness (Figure 4F) confirmed this observation, revealing significantly greater dermal regeneration in the CePC group (294.3 ± 22.5 μm) compared to the sham group (125.6 ± 6.1 μm). Given the critical role of angiogenesis in wound healing, neovascularization was evaluated in day 14 tissue samples by using CD31 immunohistochemistry (Figure 4D). Visual inspection revealed a substantially higher density of CD31-positive microvessels within the granulation tissue of CePC-treated wounds. Quantitative analysis of the vascularized area (Figure 4G) confirmed an 8.61-fold increase in the CePC group (105.1 μm2) relative to the sham group (12.2 μm2). The angiogenic activity of the P/C group (17.8 μm2) showed improvement compared with the sham group but remained significantly lower than that of the CePC group. The expression of VEGF in the wound bed was analyzed via qPCR (Figure 4H). Consistent with the histomorphometric data, the transcriptional level of VEGF was significantly upregulated in the CePC group. An elevated transcriptional level was also observed in the P/C group. CePC modulates macrophage polarization and ameliorates the inflammatory microenvironment in PI wounds To investigate the immunomodulatory effect of CePC, we first analyzed macrophage polarization within the wound bed on day 7, using immunofluorescence co-staining for the M1 marker CD86 and the M2 marker CD206. In the sham group, a predominance of CD86+ M1 macrophages was observed, with scarcely detectable CD206+ M2 macrophages. In contrast, wounds treated with the CePC membrane displayed a marked shift toward an M2-dominant phenotype, evidenced by a substantial increase in CD206+ cells and a concomitant significant decrease in CD86+ cells (Figures 5A and S3). Quantitative analysis revealed that the CePC group exhibited the highest CD206 fluorescence intensity at 263.09, compared with 10.89, 142.73, and 144.93 in the sham, PCL, and P/C groups, respectively (Figure 5B). CePC ameliorates the inflammatory microenvironment in PI wounds (A and B) Representative immunofluorescence staining images of CD86 and CD206 (A), and the corresponding quantitative analysis (B); CD86 and CD206, (H2O2 vs. H2O2 + CePC), p < 0.0001. Scale bars: 100 μm (A). (C–F) qPCR analysis of the transcriptional levels of the pro-inflammatory cytokines IL-1β (C), IL-6 (D), and IFN-γ (E) and the anti-inflammatory cytokine IL-10 (F). For H2O2 vs. H2O2 + CePC, p = 0.0001 (C), p < 0.0001 (D), p < 0.0001 (E), and p < 0.0001 (F). Error bars indicate the mean ± standard deviation, n = 3 biologically independent samples. Statistical significance was determined by one-way ANOVA followed by Tukey’s HSD post hoc test. ns, not significant; ∗∗∗, p < 0.001. To further characterize the inflammatory microenvironment, we quantified the expression of key cytokines in wound tissue. qPCR analysis showed that CePC treatment significantly downregulated the transcriptional levels of the pro-inflammatory cytokines IL-1β, IL-6, and IFN-γ compared with the sham group (Figures 5C–5E). Notably, the expression of IL-1β in the CePC group was reduced to 44% of the sham level, IL-6 expression was suppressed to 87%, and IFN-γ expression decreased to 40%. Conversely, the transcriptional level of the anti-inflammatory cytokine IL-10 was significantly upregulated in the CePC group (Figure 5F), reaching a level 4.62-fold higher than that in the sham group. To directly assess the immunomodulatory capacity of CePC on macrophages, we also analyzed the expression of M1 and M2 markers in RAW264.7 cells under different treatment conditions, using qPCR. As shown in Figure S5, stimulation with H2O2 significantly upregulated the expression of M1 markers iNOS compared with the control group, confirming successful M1 polarization. Conversely, treatment with CePC under H2O2 markedly increased the expression of M2 markers Arg1, indicating CePC reversed the polarization of M1 to state M2. Discussion In this study, we successfully engineered a multifunctional electrospun nanocomposite dressing, CePC, by incorporating ultra-fine, square-shaped nCeO2 (∼5 nm) into a hybrid PCL-collagen matrix. The resulting composite membrane exhibited ideal physicochemical properties for wound management, including a biomimetic nanofibrous architecture, enhanced hydrophilicity, superior mechanical robustness, and a tunable degradation profile. The sustained release profile provides direct experimental evidence supporting the “sustained” ROS-scavenging capacity of the CePC membrane, confirming that the continuous antioxidant and therapeutic effects observed in both in vitro and in vivo studies are indeed underpinned by the prolonged release of nCeO2 from the dressing. In summary, the CePC membrane exhibits excellent biocompatibility, as demonstrated by the non-cytotoxic nature of nCeO2 in vitro, the absence of histopathological organ damage, and the maintenance of normal hematological homeostasis in vivo. These findings collectively affirm its biosafety and suitability for long-term wound dressing applications. Collectively, these findings reveal a consistent pattern of cellular responses to CePC treatment, suggesting a potential mechanistic link between its antioxidant activity, activation of the Nrf2/HO-1 pathway, and subsequent cytoprotective effects. The nCeO2 component likely functions as a nanozyme, quenching excessive ROS and thereby contributing to the observed cytoprotective effects. This reduction in oxidative stress is associated with two downstream outcomes: maintenance of endothelial cell proliferative capacity and a shift in the cellular transcriptome characterized by reduced pro-inflammatory cytokine and enhanced VEGF expressions. The significant upregulation of VEGF is particularly critical, as it directly links the antioxidant and anti-inflammatory actions of CePC to the stimulation of angiogenesis. These findings reveal that CePC treatment is associated with activation of the Nrf2/HO-1 pathway, which may represent an important mechanism contributing to its cytoprotective effects. However, we acknowledge that definitive validation of this pathway as the causal mediator would require targeted inhibition or genetic knockout experiments, which represent important directions for future investigation. This multipronged activity—combining ROS scavenging, anti-inflammation, and pro-angiogenic signaling—positions CePC as a comprehensive therapeutic dressing capable of actively reshaping the hostile microenvironment of chronic wounds like PIs, thereby facilitating the transition from a stagnant inflammatory phase to a productive proliferative and regenerative phase. Meanwhile, we recognize that while our data demonstrate strong correlations between CePC treatment, ROS reduction, Nrf2/HO-1 pathway activation, and functional improvements, the proposed mechanistic sequence remains associative rather than definitively causal. Direct pathway perturbation experiments, such as Nrf2 siRNA knockdown or using specific inhibitors of downstream effectors, would be necessary to establish a causal relationship. These studies represent important future directions to validate and refine our mechanistic understanding of CePC’s therapeutic action. The in vivo results strongly demonstrated that CePC membranes actively promote stress injury healing through angiogenesis. The accelerated wound closure, increased dermal thickness, and particularly the significantly enhanced functional neovascularization directly correlated with the upregulated VEGF observed in vitro, which is essential for delivering nutrients and oxygen to the healing wounds. These results establish that the CePC membrane actively reshapes the pathological inflammatory milieu of PIs, which is a critical step in breaking the cycle of non-healing. The dramatic shift in macrophage polarization from the M1 to the M2 phenotype is particularly significant. The observed increase in the M2/M1 ratio in the CePC group was temporally associated with the enhanced vascularization and tissue regeneration, documented in “in vivo therapeutic efficacy of CePC in promoting vascularized healing of PIs,” suggesting a potential role for immunomodulation in the angiogenic outcomes observed in this study. The shift in macrophage polarization from the M1 to the M2 phenotype is particularly noteworthy, as M2 macrophages are known to secrete growth factors that promote angiogenesis, matrix deposition, and tissue remodeling. The temporal association between the increased M2/M1 ratio and enhanced vascularization in CePC-treated wounds suggests that immunomodulation may contribute to the pro-angiogenic effects observed. However, we acknowledge that direct causality has not been established, and further studies employing macrophage depletion or polarization inhibition would be necessary to definitively validate this mechanistic link. By scavenging ROS, CePC may create a microenvironment conducive to M2 differentiation. Furthermore, the significant downregulation of IL-1β, IL-6, and IFN-γ, key drivers of inflammation and tissue destruction—and the concurrent upregulation of IL-10, a potent anti-inflammatory and fibrosis-suppressing cytokine—collectively demonstrated that CePC orchestrates a balanced cytokine profile conducive to the resolution of inflammation and progression to the proliferative phase of healing. This multifaceted modulation of the immune response positions CePC not merely as a passive dressing but as an active therapeutic agent capable of correcting the dysfunctional inflammation characteristic of chronic wounds. These findings establish CePC as a multifaceted therapeutic platform that actively reprograms the chronic wound microenvironment, offering a promising and synergistic strategy for advanced PI treatment. While the current study focuses on non-infected wound healing, we acknowledge that bacterial infections frequently complicate chronic wounds in clinical settings. Given the reported peroxidase-like activity of CeO2-based nanozymes, our material may possess intrinsic antibacterial properties. Future investigations will systematically evaluate the antibacterial efficacy of CePC against common wound pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa, potentially extending its therapeutic utility to infected wound models. While the current study demonstrates the superior efficacy of CePC compared with its individual components (PCL and P/C), we acknowledge that benchmarking against clinically established wound dressings would further enhance translational relevance. We will include commonly used clinical dressings such as silver-containing or hydrocolloid products as positive controls to directly evaluate the therapeutic advantages of CePC relative to existing standard-of-care therapies in the future. Limitations of the study While this study demonstrates the promising therapeutic potential of the CePC nanocomposite dressing for PI treatment, several limitations should be acknowledged. First, the current investigation focused exclusively on non-infected wound healing models. Given that bacterial infections frequently complicate chronic wounds in clinical settings, the absence of antimicrobial evaluation represents a significant gap. Although CeO2-based nanozymes are known to possess peroxidase-like activity that may confer intrinsic antibacterial properties, systematic validation against common wound pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa has not yet been performed.19 Future studies should extend the therapeutic evaluation of CePC to infected wound models to fully establish its clinical applicability. Second, although we demonstrated the superior efficacy of CePC compared with its individual components (PCL and P/C blends), the study lacks direct benchmarking against clinically established wound dressings. Comparative analysis with standard-of-care products—such as silver-containing dressings or hydrocolloid materials—would provide critical context for assessing the translational advantages of CePC relative to existing therapies. Such comparisons are essential to position CePC within the current clinical landscape and to support its potential for future clinical translation. Addressing these limitations in subsequent investigations will further strengthen the clinical relevance and therapeutic promise of this multifunctional nanocomposite dressing. Resource availability Lead contact Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Yue Tang (tangyue127@163.com). Materials availability This study did not generate new unique reagents. Data and code availability •Data reported in this paper will be shared by the lead contact upon request. Data reported in this paper will be shared by the lead contact upon request. •This paper does not report original code. This paper does not report original code. •Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Acknowledgments The care and use of all animals were conducted in accordance with the guiding principles of the Animal Research Ethics Committee of Institutional Animal Care and Use Committee (IACUC), Sun Yat-sen University (experimental program no. SYSU-IACUC-2025-B2385), and were strictly in compliance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Author contributions Conceptualization, Y.T., H.C., and L.Z.; methodology, Z.M., J.W., and H.C.; investigation, Z.M., H.Y., C.Q., Y.Z., and H.C.; writing – original draft, J.W. and Z.M.; writing – review & editing, H.T., Y.Z., L.Z., and H.C.; resources, Y.T., H.C., L.Z., and Z.M.; supervision, L.Z. and Y.T. Declaration of interests The authors declare no competing interests. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERAntibodiesCD86 monoclonal antibodyBioLegend305401,105001CD206 (MMR) monoclonal antibodyCell Signaling Technology24595Anti-CD31 antibodyCell Signaling Technology77699Chemicals, peptides, and recombinant proteinsCerium ammonium nitrate (Ce(NH4)2(NO3)6)Aladdin Biochemical Technology16774-21-3Polyvinylpyrrolidone (PVP)Sigma-Aldrich9003-39-8polycaprolactone (PCL)Sigma-AldrichZ694657type I collagen from bovine tendon, N, N-dimethylformamide (DMF)Sigma-AldrichC0130tetrahydrofuran (THF)Sigma-Aldrich186562Sodium hydroxide (NaOH)Sinopharm Chemical Reagent567530anhydrous ethanolSinopharm Chemical Reagent459836phosphate-buffered saline (PBS)Sinopharm Chemical ReagentP2272Dulbecco’s Modified Eagle Medium (DMEM)Gibco11965092Fetal bovine serum (FBS)Gibco100991411% penicillin-streptomycin (PS)Gibco15140163Endothelial Cell Growth Medium (EGM-2, Lonza, Switzerland)LonzaCC-3162CCK-8 assay kitDojindoCK04MTTSigmaM5655Nrf2 ELISA kitsAbcamab207223HO-1ELISA kitsAbcamab229429Experimental modelsC57BL/6 miceGempharmatech Co., LtdRRID:IMSR_JAX:000664Human Umbilical Vein Endothelial CellsCellverse Co., LtdRRID:CVCL_2959HaCaT KeratinocytesCellverse Co., LtdRRID:CVCL_0038Mouse fibroblast cells (L929)Cell Bank of the Chinese Academy of SciencesRRID: CVCL_0462SoftwareMalvern ZS XplorerMalvern Panalytical Ltd.https://www.malvernpanalytical.comImageJNational Institutes of HealthRRID:SCR_003070GraphPad PrismGraphPad SoftwareRRID:SCR_002798 Experimental model and study participant details Animal model •Species/Strain: C57BL/6 mice Species/Strain: C57BL/6 mice •Sex and Age: Male, 8–12 weeks old Sex and Age: Male, 8–12 weeks old •Developmental Stage: Adult Developmental Stage: Adult •Maintenance and Care: Mice were housed under standard laboratory conditions with ad libitum access to food and water. The animal use protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Sun Yat-Sen University (Approval No. SYSU-IACUC-2025-B2385). All procedures were conducted in strict compliance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Maintenance and Care: Mice were housed under standard laboratory conditions with ad libitum access to food and water. The animal use protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Sun Yat-Sen University (Approval No. SYSU-IACUC-2025-B2385). All procedures were conducted in strict compliance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. •Consideration of Sex Influence: This study utilized only male mice to minimize variability in wound healing responses that can be influenced by estrous cycle in females. While this provides internal consistency, it may limit the generalizability of the findings to female subjects, which should be considered as a limitation of the study. Consideration of Sex Influence: This study utilized only male mice to minimize variability in wound healing responses that can be influenced by estrous cycle in females. While this provides internal consistency, it may limit the generalizability of the findings to female subjects, which should be considered as a limitation of the study. Cell lines •Human Umbilical Vein Endothelial Cells (HUVECs): Primary endothelial cells derived from human umbilical veins were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Endothelial Cell Growth Medium-2 (EGM-2, Lonza, Switzerland) at 37°C in a humidified atmosphere containing 5% CO2. Human Umbilical Vein Endothelial Cells (HUVECs): Primary endothelial cells derived from human umbilical veins were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Endothelial Cell Growth Medium-2 (EGM-2, Lonza, Switzerland) at 37°C in a humidified atmosphere containing 5% CO2. •HaCaT Keratinocytes: Immortalized human keratinocyte cell line purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin-streptomycin (PS, Gibco, USA) at 37°C in a humidified atmosphere containing 5% CO2. HaCaT Keratinocytes: Immortalized human keratinocyte cell line purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin-streptomycin (PS, Gibco, USA) at 37°C in a humidified atmosphere containing 5% CO2. •L929 Fibroblasts: Mouse fibroblast cell line obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin-streptomycin (PS, Gibco, USA) at 37°C in a humidified atmosphere containing 5% CO2. L929 Fibroblasts: Mouse fibroblast cell line obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin-streptomycin (PS, Gibco, USA) at 37°C in a humidified atmosphere containing 5% CO2. •Cell culture conditions: All cells were subcultured when reaching approximately 80%–90% confluence under standard cell culture conditions. Cell culture conditions: All cells were subcultured when reaching approximately 80%–90% confluence under standard cell culture conditions. •Cell line authentication and mycoplasma testing: The HaCaT and HUVEC cell lines used in this study were authenticated by the suppliers prior to use. Cell identity was further confirmed based on typical morphological characteristics and growth behavior during routine culture. All cell lines were tested for mycoplasma contamination using a commercial mycoplasma detection kit, and no contamination was detected. Cell line authentication and mycoplasma testing: The HaCaT and HUVEC cell lines used in this study were authenticated by the suppliers prior to use. Cell identity was further confirmed based on typical morphological characteristics and growth behavior during routine culture. All cell lines were tested for mycoplasma contamination using a commercial mycoplasma detection kit, and no contamination was detected. Method details Synthesis of square-shaped cerium dioxide nanoparticles (nCeO2) Square-shaped cerium dioxide (CeO2) ultra-fine nanoparticles (nCeO2) with a particle size of 5–10 nm were synthesized via a modified hydrothermal method.20,21 Briefly, an aqueous solution of cerium ammonium nitrate (0.1 M) was mixed with PVP (1 wt %) as a structural-directing agent under alkaline conditions (adjusted to pH 10 using 1 M NaOH). The mixture was transferred into a 50 mL Teflon-lined stainless-steel autoclave and heated at 150 °C for 12 h. After natural cooling to room temperature, the product was collected by centrifugation (10,000 rpm, 10 min), washed repeatedly with deionized water and absolute ethanol, and finally dried in a vacuum oven at 60 °C overnight. Fabrication of electrospun nanofibrous membranes The electrospun nanofibrous membranes were fabricated using an electrospinning setup. The nCeO2 nanoparticles were uniformly dispersed in a polymer solution via ultrasonication (30 min, 200 W). Two types of polymer solutions were prepared: (1) a pure PCL solution (10 wt % in a mixed solvent of DMF/THF, 7:3 v/v), and (2) a PCL/collagen (8:2 w/w) mixed solution (10 wt % total polymer concentration in the same solvent mixture). The nanoparticle-polymer suspension (containing 2 wt % nCeO2 relative to polymer weight) was then loaded into a 10 mL syringe equipped with a 21-gauge stainless-steel needle. Electrospinning was performed under controlled parameters: an applied voltage of 15 kV, a feeding rate of 1.0 mL/h, and a collection distance of 15 cm. The obtained composite nanofibrous membranes, designated as P/C (PCL/nCeO2) and CePC (PCL-collagen/nCeO2), respectively, were subsequently vacuum-dried at room temperature for 48 h to remove residual solvent. A pure PCL membrane was also prepared as a control under identical conditions. Characterization The morphology and microstructure of nCeO2 nanoparticles were characterized using a JEOL JEM-2100 transmission electron microscope (TEM, JEOL Ltd., Japan). Additional high-resolution imaging was conducted on a Thermo Fisher Scientific Spectra 300 aberration-corrected TEM (AC-TEM, Thermo Fisher Scientific, USA). The surface chemistry of nCeO2 was analyzed by X-ray photoelectron spectroscopy (XPS, Thermo Scientific K-Alpha, Thermo Fisher Scientific, USA), while its crystallographic structure was examined using an X-ray diffractometer (XRD, Bruker D8 ADVANCE, Bruker, Germany) with Cu Kα radiation (λ = 1.5406 Å). The surface topography of the electrospun membranes (PCL, P/C, and CePC) was observed using a field-emission scanning electron microscope (FE-SEM, Hitachi SU8010, Hitachi, Japan). The porosity of the membranes was determined via the liquid displacement method using anhydrous ethanol. The swelling ratio was measured by immersing pre-weighed dried membrane samples in PBS (pH 7.4) at 37 °C for 24 h. Mechanical properties, including tensile stress and elastic modulus, were evaluated using a universal testing machine (Instron 5567, Instron, USA) with a crosshead speed of 5 mm/min (sample dimension: 20 mm × 5 mm). Finally, the in vitro degradation behavior was assessed by incubating the membranes in PBS at 37 °C and monitoring the weight loss at predetermined time intervals over 28 days. Electrospun membranes from all three groups (PCL, P/C, and CePC) will be prepared under identical conditions and cut into 1 cm × 1 cm squares. The samples will be carefully mounted on glass slides to ensure a flat surface for accurate measurement. Static water contact angles will be measured using a contact angle goniometer (Krüss DSA25, Germany) at room temperature. A 5 μL droplet of deionized water will be gently deposited onto the membrane surface using a microsyringe. The droplet image will be captured immediately (within 5 s) to minimize the effects of absorption and evaporation. At least five different positions on each sample will be measured, and three independent samples per group will be tested. In vitro release study of nCeO2 from CePC membrane To investigate the release behavior of cerium dioxide nanoparticles (nCeO2) from the CePC electrospun membrane and substantiate the claimed “sustained” ROS scavenging capacity, an in vitro release study was conducted. CePC membrane samples were cut into 1 cm × 1 cm pieces (n = 3 per time point) and accurately weighed. Each sample was immersed in 10 mL of phosphate-buffered saline (PBS, pH 7.4) and incubated at 37°C with gentle shaking at 100 rpm to simulate physiological conditions. At predetermined time intervals (1, 3, 5, 7, 14, 21, and 28 days), 1 mL of the release medium was collected and replaced with an equal volume of fresh pre-warmed PBS to maintain sink conditions. The collected samples were stored at −20°C until analysis. The cerium ion (Ce) concentration in the release medium was quantified using inductively coupled plasma mass spectrometry (ICP-MS, Agilent 7900, USA). The cumulative release percentage was calculated using the following formula: where Mt represents the cumulative mass of cerium released at time t, and M0 represents the initial total cerium mass loaded in the CePC membrane sample. The release profile was plotted as cumulative release percentage versus time to characterize the release kinetics. Cell culture Human immortalized keratinocytes (HaCaT cells) and human umbilical vein endothelial cells (HUVECs) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Mouse fibroblast cells (L929) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). HaCaT and L929 cells were routinely cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, USA), supplemented with 10% fetal bovine serum (FBS, Gibco, USA) and 1% penicillin-streptomycin (PS, Gibco, USA). HUVECs were cultured in Endothelial Cell Growth Medium (EGM-2, Lonza, Switzerland). All cells were maintained in a humidified incubator at 37°C with 5% CO2 and subcultured upon reaching 80–90% confluence. Biocompatibility and biosafety assessment Cytotoxicity and cell proliferation assessment in vitro The potential cytotoxicity of the synthesized cerium dioxide nanoparticles (nCeO2) was evaluated in vitro using L929, HaCaT, HUVEC cells. Cells were seeded in 96-well plates at a density of 5×103 cells/well. After 24-h incubation, the culture medium was replaced with fresh CePC medium containing P/C, PCL, and varying concentrations of nCeO2 nanoparticles (μg/mL). Following 24 or 48 h of exposure, cell viability was assessed using the Cell Counting Kit-8 (CCK-8, Dojindo, Japan) assay according to the manufacturer’s instructions. The absorbance at 450 nm was measured using a microplate reader (BioTek, USA). Cell proliferation was independently evaluated using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay under identical treatment conditions. In vivo systemic biosafety evaluation in a diabetic wound model A pressure injury mouse model was established (See pressure injury model and experimental design for details). The mice wounds were treated with CePC membranes. Hematological Analysis: Blood samples were collected from the orbital sinus of mice at different time points post-wound application (day 0, 5, 10, 15, 20). Complete blood counts (CBC), including white blood cell (WBC), red blood cell (RBC), platelet (PLT) counts, and hemoglobin (HGB) levels, were analyzed using an automated hematology analyzer (Sysmex XN-1000, Sysmex Corporation, Japan) to monitor systemic inflammatory responses and potential hematotoxicity. Histopathological Examination of Vital Organs: At the endpoint of the study (28 days post-surgery), mice were euthanized. Major vital organs, including the heart, liver, spleen, lungs, and kidneys, were harvested, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. Tissue sections (5 μm thickness) were stained with hematoxylin and eosin (H&E) following standard protocols. The stained sections were examined under a light microscope (Olympus BX53, Japan) to assess pathological changes, inflammation and toxicity. RAW264.7 macrophages polarization To evaluate the immunomodulatory effect of CePC on macrophage polarization, RAW264.7 murine macrophages were cultured and treated under various conditions. Cells were seeded in 6-well plates at a density of 2 × 105 cells per well and allowed to adhere overnight. Subsequently, cells were co-cultured with sterilized electrospun membrane extracts (PCL, P/C, and CePC) prepared as described before. The related polarization identification was performed using PCR, as detailed in Methods Section 2.11. In vitro antioxidant assessment Experimental grouping To evaluate the cellular antioxidant and anti-senescence effects of the electrospun membranes, HUVECs were subjected to an in vitro oxidative stress model. HUVECs were seeded and allowed to adhere overnight. Subsequently, the cells were co-cultured with different sterilized electrospun membrane samples (PCL, P/C, and CePC) placed in Transwell inserts, and simultaneously exposed to 200 μM hydrogen peroxide (H2O2) in the culture medium for 24 h to induce premature senescence and oxidative damage. Accordingly, the experimental groups were designated as follows: (1) Control: cells cultured in normal medium; (2) H2O2: cells treated with H2O2 only (positive control for oxidative stress/senescence); (3) H2O2 + PCL; (4) H2O2 + P/C; and (5) H2O2 + CePC. Measurement of intracellular reactive oxygen species (ROS) levels Intracellular ROS levels were measured using the fluorescent probe DCFH-DA (Beyotime, China). Following the treatment, cells were washed with PBS and incubated with 10 μM DCFH-DA in serum-free medium at 37°C for 30 min in the dark. After washing twice with PBS to remove excess probe, the fluorescence intensity (excitation/emission = 488/525 nm) was immediately measured using a fluorescence microplate reader (BioTek, USA). Fluorescence images were also captured using a fluorescence microscope (Olympus, Japan). The relative fluorescence intensity was normalized to that of the Control group. Assessment of cell proliferation under oxidative stress (MTT assay) Cell proliferation under oxidative stress conditions was evaluated using the MTT assay. After the 24-h co-culture and H2O2 treatment as described above, the medium was replaced with fresh medium containing 0.5 mg/mL MTT (Sigma, USA) and incubated for 4 h at 37°C. The formazan crystals formed were then dissolved in dimethyl sulfoxide (DMSO). The absorbance of the resulting solution was measured at 570 nm using a microplate reader. Cell viability/proliferation was expressed as a percentage relative to the Control group. HUVEC angiogenesis assay To directly assess the pro-angiogenic capacity of CePC, Matrigel tube formation assays were performed using human umbilical vein endothelial cells (HUVECs). Growth factor-reduced Matrigel (Corning) was thawed overnight at 4°C and polymerized in 96-well plates (50 μL/well) at 37°C for 30 min. HUVECs were cultured in endothelial cell medium (ECM), starved in low-serum medium (1% FBS) for 6 h, then harvested and seeded onto the polymerized Matrigel at a density of 2 × 104 cells per well in 100 μL of medium containing: control (normal culture medium), CePC extract (100 μg/mL, prepared from degradation supernatants as described in our degradation studies), positive control (VEGF, 10 ng/mL), or negative control (suramin, 50 μM, an angiogenesis inhibitor). After 48 h of incubation at 37°C, tube formation was observed and photographed using an inverted microscope (Olympus, 4× objective), with five random fields per well captured for quantification. Enzyme-linked immunosorbent assay (ELISA) for Nrf2 and HO-1 quantification To assess activation of the Nrf2/HO-1 pathway, HUVECs were treated for 24 h with control, H2O2, H2O2 + CePC, H2O2 + P/C, H2O2 + PCL. Cells were lysed in RIPA buffer with protease/phosphatase inhibitors, and protein concentrations were determined by BCA assay. Nrf2 and HO-1 levels in lysates were quantified using ELISA kits (Abcam, ab207223 and ab229429) per manufacturer instructions. Briefly, samples were added to pre-coated plates, incubated with detection antibody, followed by HRP-conjugated secondary antibody. Absorbance was read at 450 nm, and concentrations were calculated from standard curves and normalized to total protein. All experiments were performed in triplicate. In vivo assessment of pressure injury wound healing Pressure injury model and experimental design Adult male wild-type C57BL/6 mice (8–12 weeks old) were purchased from GemPharmatech Co., Ltd. (Nanjing, China). A clinically relevant pressure injury model was established in mice using a magnetic ischemia-reperfusion system. Following a one-week acclimatization under SPF conditions, mice were randomly assigned to experimental or sham groups. A sterile, biocompatible disc magnet (internal magnet) was subcutaneously implanted on the dorsum under isoflurane anesthesia. After 24 h of recovery, an identical external magnet was applied over the skin directly above the implant, creating controlled pressure to induce local ischemia. To mimic cyclic pressure relief in clinical settings, a standardized ischemia-reperfusion protocol was implemented: 2 h of continuous magnetic pressure (ischemia) followed by 1 h of magnet removal (reperfusion), repeated for three cycles (9 h total). This regimen reliably produces pressure injury-like lesions. In brief, following the successful establishment of the pressure ulcer model, two full-thickness excisional wounds (diameter: 8 mm) were created on the dorsum of each mouse using a sterile biopsy punch. The mice were then randomly divided into four treatment groups (n = 18 per group): (1) Sham (wounds left untreated), (2) PCL (covered with pure PCL membrane), (3) P/C (covered with PCL-collagen composite electrospun membrane), and (4) CePC (covered with PCL-collagen/nCeO2 composite electrospun membrane). All dressings were secured with 3M Tegaderm transparent film and changed every 3 days throughout the study period. Histological and histomorphometric analysis Hematoxylin and eosin (H&E) staining was performed using a commercially available staining kit (Servicebio, China) according to the manufacturer’s standard protocol. Briefly, paraffin-embedded sections (5 μm thick) were deparaffinized in xylene (Sinopharm, China) and rehydrated through a graded ethanol series (100%, 95%, 80%, and 70%; Sinopharm, China). Subsequently, sections were stained with hematoxylin solution (Servicebio, China) for 3 min, followed by differentiation in 1% acid alcohol (1% HCl in 70% ethanol, prepared in-house). After bluing in Scott’s tap water substitute (Servicebio, China) for 1 min, sections were counterstained with eosin Y solution (Servicebio, China) for 30 s. Finally, sections were dehydrated through a reverse ethanol series, cleared in xylene, and mounted with neutral balsam (Servicebio, China). Representative images of the wound bed were captured using a light microscope (Olympus BX53, Japan). Dermal thickness at the wound center was measured from the epidermal-dermal junction to the subcutaneous border on H&E-stained images using ImageJ software (National Institutes of Health, USA, version 1.53). Three measurements were taken per sample and averaged for statistical analysis. Immunohistochemical analysis of angiogenesis To evaluate neovascularization, wound tissues collected on day 14 were fixed in 4% paraformaldehyde, paraffin-embedded, and sectioned at 5 μm thickness. After deparaffinization and rehydration, antigen retrieval was performed by boiling the sections in sodium citrate buffer (10 mM, pH 6.0; ZSGB-BIO, China) for 15 min. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide (H2O2; Sigma-Aldrich, USA) for 10 min at room temperature. Non-specific binding was blocked by incubating with 5% normal goat serum (Vector Laboratories, USA) in PBS for 30 min at room temperature. Sections were then incubated overnight at 4°C with a rabbit anti-mouse CD31 primary antibody (Cell Signaling Technology, USA; 1:200 dilution). After washing, sections were incubated with a horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (ZSGB-BIO, China) for 30 min at room temperature. Positive signals were visualized using a 3,3′-diaminobenzidine (DAB) chromogen kit (ZSGB-BIO, China), following the manufacturer’s instructions. Nuclei were counterstained with hematoxylin (Sigma-Aldrich, USA) for 1 min. After dehydration and mounting, the stained sections were scanned using a digital slide scanner. The vascularized area was quantified by calculating the percentage of CD31-positive (brown) area relative to the total wound area in three randomly selected high-power fields (200× magnification) per sample using ImageJ software (National Institutes of Health, USA). Analysis of macrophage polarization Tissue sections from day 7 post-wounding were subjected to immunofluorescence (IF) double staining. Sections were incubated overnight at 4°C with the following primary antibodies diluted in PBS containing 5% bovine serum albumin (BSA): rat anti-mouse CD86 monoclonal antibody (BioLegend, USA; 1:100 dilution) and rabbit anti-mouse CD206 (MMR) monoclonal antibody (Cell Signaling Technology, USA; 1:200 dilution). After washing, sections were incubated for 1 h at room temperature with corresponding fluorescent secondary antibodies: Alexa Fluor 488-conjugated goat anti-rat IgG (H + L) (Invitrogen, USA; 1:500 dilution) and Alexa Fluor 594-conjugated goat anti-rabbit IgG (H + L) (Invitrogen, USA; 1:500 dilution). Nuclei were counterstained with DAPI (Sigma-Aldrich, USA; 1 μg/mL) for 5 min at room temperature. Representative images were captured using a fluorescence microscope (Olympus BX53, Japan) equipped with appropriate filter sets. RNA isolation and quantitative real-time (q-PCR) RNA from the treated cells was extracted using AllPrep DNA/RNA Mini kit (Dusseldorf, GRE) and cDNA was synthesized using SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, USA). The mRNA expression was determined by QPCR in a CFX96 thermal cycler (Bio-rad, USA). Data are presented in arbitrary units and calculated by the 2ˆ(-ΔΔCT) method. Primer sequences were obtained from the NIH qPrimerDepot (http://mouseprimerdepot.nci.nih.gov) and provided by Integrated DNA technologies. The mRNA level of BMSCs was detected by the same method as above. The primers used in this study are shown as Table S1. Quantification and statistical analysis All experiments were performed at least in triplicate, and data are presented as mean ± standard deviation (SD). Statistical analyses were conducted using GraphPad Prism 9.5.1 software (GraphPad Software, Inc., USA). For comparisons between two groups, an unpaired two-tailed Student’s t test was used. For comparisons involving three or more groups, one-way analysis of variance (ANOVA) was performed, followed by Tukey’s honestly significant difference (HSD) post hoc test for multiple comparisons. For two-factor experiments involving multiple groups and time points, two-way ANOVA was used, followed by Šidák’s multiple comparisons test. Homogeneity of variances was assessed using Levene’s test, and normality was verified using the Shapiro–Wilk test. In all analyses, a p-value of less than 0.05 was considered statistically significant. Specific statistical values (t values for t-tests, F values with degrees of freedom for ANOVA) and exact p-values are reported in the corresponding figure captions. Footnotes Supplemental information can be found online at https://doi.org/10.1016/j.isci.2026.116096. Contributor Information Lu Zhang, Email: zhanglu1@sysush.com. Haibin Chen, Email: chenhaibin@sysush.com. Yue Tang, Email: tangyue127@163.com. Supplemental information Document S1. Figures S1–S5 and Tables S1 and S2 References Associated Data Supplementary Materials Document S1. Figures S1–S5 and Tables S1 and S2 Data Availability Statement •Data reported in this paper will be shared by the lead contact upon request. Data reported in this paper will be shared by the lead contact upon request. •This paper does not report original code. This paper does not report original code. •Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.